Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

Cited by (525)

Items 201–300 of 525

1. Statins and New-Onset Diabetes
   Marcin Barylski, Dragana Nikolić, Maciej Banach, Peter Paul Toth, Giuseppe Montalto, Manfredi Rizzo · 2014 · Current Pharmaceutical Design
2. Diabetes and Dyslipidemia
   Kenneth R. Feingold, Carl Grünfeld · 2023 · Contemporary cardiology
3. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes
   Hanney Gonna, Kausik Kumar Ray · 2019 · Diabetes Obesity and Metabolism
4. Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida
   Grupo de Trabajo sobre Diabetes y Enfermedades Cardiovasculares de la Sociedad Europea de Cardiología (ESC), de la Sociedad Europea para el Estudio de la Diabetes (EASD) · 2007 · Revista Española de Cardiología
5. Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy
   David J Decewicz, David M. Neatrour, Amy Burke, Mary Jane Haberkorn, Heather L. Patney, Marina Vernalis, Darrell L. Ellsworth · 2009 · Lipids in Health and Disease
6. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin
   Kevin A. Bybee, Johan Lee, James Henry O’Keefe · 2008 · Current Medical Research and Opinion
7. Prevalencia del síndrome metabólico y de sus componentes en pacientes con síndrome coronario agudo
   Ana Jover, Emili Corbella, Anna Muñoz, Jesús Millán, Xavier Pintó, Alipio Mangas, Manuel Zúñiga, Juan Pedro‐Botet, Antonio Hernández‐Mijares · 2011 · Revista Española de Cardiología
8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy
   Sergio Fazio · 2008 · Clinical Therapeutics
9. Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting
   Howard Steven Friedman, Srinivasan Rajagopalan, Jaime P. Barnes, Hal Roseman · 2011 · Clinical Therapeutics
10. Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society
    Marcello Casaccia Bertoluci, Augusto Pimazoni Netto, Antônio Carlos Pires, Antônio Eduardo Pereira Pesaro, Beatriz D'Agord Schaan, Bruno Caramelli, Carísi Anne Polanczyk, Carlos Vicente Serrano Junior, Danielle Menosi Gualandro, Domingos Augusto Cherino Malerbi et al. · 2014 · Diabetology & Metabolic Syndrome
11. Effect of Diabetea tea ™ consumption on inflammatory cytokines and metabolic biomarkers in type 2 diabetes patients
    Fadia Fouad Mahmoud, Ebaa Al‐Ozairi, David Donald Haines, Ladislav Novotný, Ali A. Dashti, Basel Ibrahim, Mohamed Abdel-Hamid · 2016 · Journal of Ethnopharmacology
12. Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
    Michel Paul Hermans, Jean‐Charles Fruchart · 2010 · Clinical Lipidology
13. High prevalence of comorbidities in older adult patients with type 2 diabetes: a cross-sectional survey
    Rana Hashemi, Soghra Rabizadeh, Amirhossein Yadegar, Fatemeh Mohammadi, Armin Rajab, Sahar Karimpour Reyhan, Seyed Arsalan Seyedi, Alireza Esteghamati, Manouchehr Nakhjavani · 2024 · BMC Geriatrics
14. Combination therapy in the management of mixed dyslipidaemia
    Christopher Paul Cannon · 2008 · Journal of Internal Medicine
15. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia
    Bing Sun, Yuan Xie, Jinfa Jiang, Yi‐Ping Wang, Xiaolin Xu, Cuimei Zhao, Feifei Huang · 2015 · Lipids in Health and Disease
16. Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis
    Robert Fleetcroft, Peter Schofield, Mark J. Ashworth · 2014 · BMC Health Services Research
17. Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India
    Raman Puri, Vimal Mehta, Paul Barton Duell, S K Wangnoo, Ashu Rastogi, Viswanathan Mohan, Abdul Hamid Zargar, Sanjay Kalra, Abhay Sahoo, S.S. Iyengar et al. · 2022 · Journal of clinical lipidology
18. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus
    Masumi Ai, Seiko Otokozawa, Ernst J. Schaefer, Bela F. Asztalos, Katsuyuki Nakajima, Peter J. Shrader, Sekar Kathiresan, James B. Meigs, Gordon H. Williams, David M. Nathan · 2009 · Clinica Chimica Acta
19. A Review of the Current Status of the Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and Metabolic Syndrome
    Michael H. Davidson · 2008 · The American Journal of Cardiology
20. Association of Younger Age With Poor Glycemic and Cholesterol Control in Asians With Type 2 Diabetes Mellitus in Singapore
    Matthias Paul Han Sim Toh, Christine Xia Wu, Helen Leong · 2011 · Journal of Endocrinology and Metabolism
21. Dyslipidemia in Adults With Diabetes
    2006 · Canadian Journal of Diabetes
22. Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Yang, Hack‐Lyoung Kim, Sang‐Hyun Kim, Min Kyong Moon · 2023 · Journal of Lipid and Atherosclerosis
23. Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus
    Sundararajan Srikanth, PRAKASH C. DEEDWANIA · 2011 · Cardiology Clinics
24. All-Cause Mortality in Patients with Type 2 Diabetes in Association with Achieved Hemoglobin A1c, Systolic Blood Pressure, and Low-Density Lipoprotein Cholesterol Levels
    Hou-Hsien Chiang, Fen‐Yu Tseng, Chih‐Yuan Wang, Chi‐Ling Chen, Yi‐Chun Chen, Ting-Ting See, Hua-Fen Chen · 2014 · PLoS ONE
25. Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
    Niina Matikainen, Marja‐Riitta Taskinen · 2012 · Current Cardiology Reports
26. Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes
    Lizheng Shi, Xin Ye, Mei Lü, Eric Qiong Wu, Hari Sharma, Darren Thomason, Vivian Andrew Fonseca · 2013 · Diabetes Care
27. Evaluación del grado de consecución de objetivos de control metabólico en pacientes con diabetes mellitus tipo 2
    María del Mar Roca-Rodríguez, Florentino Carral San Laureano, Gloria Baena‐Nieto, Manuel Aguilar‐Diosdado · 2010 · Endocrinología y Nutrición
28. Clinical Significance of Recent Lipid Trials on Reducing Risk in Patients with Type 2 Diabetes Mellitus
    Peter H. Jones · 2006 · The American Journal of Cardiology
29. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects
    Ana Lucia de Almeida Kater, Marcelo Costa Batista, Sandra Roberta G. Ferreira · 2010 · Diabetology & Metabolic Syndrome
30. Diabetes and Vascular Disease: Is It All About Glycemia?
    Alessandra Vecchié, Fabrizio Montecucco, Federico Carbone, Franco Dallegri, Aldo Bonaventura · 2019 · Current Pharmaceutical Design
31. The Role of Lipid‐lowering Therapy in Preventing Coronary Heart Disease in Patients with Type 2 Diabetes
    Dean G. Karalis · 2007 · Clinical Cardiology
32. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update
    Gregory A. Nichols, Soma S. Nag, Wiley Chan · 2007 · American Heart Journal
33. Application of the Screening for Heart Attack Prevention and Education Task Force Recommendations to an Urban Population Observations From the Dallas Heart Study
    Raphael See · 2008 · Archives of Internal Medicine
34. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study
    Jesús Millán Núñez-Cortés, Aleix Cases, Juan Francisco Ascaso Gimilio, Vivencio Barrios, Vicente Pascual Fuster, Juan Pedro‐Botet, Xavier Pintó, Adalberto Serrano Cumplido · 2016 · American Journal of Cardiovascular Drugs
35. PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure
    Neville F. Mistry, Sharon Cresci · 2008 · Heart Failure Reviews
36. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels
    Laurent Querton, Martin Buysschaert, Michel Paul Hermans · 2012 · Journal of clinical lipidology
37. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets
    Paul J.W.H. Kappelle, Geesje M. Dallinga‐Thie, Robin P. F. Dullaart · 2009 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
38. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium–glucose co-transporter 2 inhibitors
    Dario Rahelić, Eugen Javor, Tomo Lucijanić, Marko Skelin · 2016 · Annals of Medicine
39. Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
    Ye Yang, Hack‐Lyoung Kim, Sang‐Hyun Kim, Min Kyong Moon, Korean Society of Lipid and Atherosclerosis · 2023 · Diabetes & Metabolism Journal
40. Diabetes and vascular disease
    PRAKASH C. DEEDWANIA, Sundararajan Srikanth · 2007 · Expert Review of Cardiovascular Therapy
41. Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
    Michel Paul Hermans, Jean‐Charles Fruchart · 2011 · Therapeutic Advances in Chronic Disease
42. Lipid-lowering agents and new onset diabetes mellitus
    Vasilios Gabriel Athyros, Κωνσταντίνος Τζιόμαλος, Asterios I. Karagiannis, Dimitri P. Mikhailidis · 2010 · Expert Opinion on Pharmacotherapy
43. Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
    Om P. Ganda, Jorge Plutzky, Santosh K. Sanganalmath, Maja Bujas‐Bobanovic, Andrew Koren, Jonas Mandel, Alexia Letierce, Lawrence A. Leiter · 2018 · Diabetes Obesity and Metabolism
44. Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study
    Seung‐Hwan Lee, Hyuk‐Sang Kwon, Yong‐Moon Park, Seung‐Hyun Ko, Yoon‐Hee Choi, Kun‐Ho Yoon, Yu‐Bae Ahn · 2014 · Diabetes & Metabolism Journal
45. Initiation and Persistence to Statin Treatment in Patients with Diabetes Receiving Glucose-Lowering Medications 1997- 2006
    Helena Domínguez, T. K. Schramm, Mette Lykke Norgaard, Steen Zabell Abildstrom, Lars Køber, C. Jørgensen, T.J. Guterbaum, Henrik Enghusen Poulsen, C. Torp-Pedersen, Gunnar Gislason · 2009 · The Open Cardiovascular Medicine Journal
46. The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management
    Pamela M. Katz, Lawrence A. Leiter, Linda Mellbin, Lars Rydén · 2014 · Diabetes and Vascular Disease Research
47. BSN723T Prevents Atherosclerosis and Weight Gain in ApoE Knockout Mice Fed a Western Diet.
    Jarrod Williams, Mark Ensor, Scott Gardner, Rebecca R. Smith, Robert A. Lodder · 2015 · PubMed
48. A cardiologist view of vascular disease in diabetes
    Christopher Lockhart, Paul Hamilton, Katherine McVeigh, Gary Eugene McVeigh · 2007 · Diabetes Obesity and Metabolism
49. Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long‐term type 2 diabetes: A cross‐sectional survey in China
    Ren, Yanfeng, Ren, Qian, Lu, Juming, Guo, Xiaohui, Huo, Xiaoxu, Ji, Linong, Yang, Xilin · 2018 · Diabetes/Metabolism Research and Reviews
50. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus
    Gissette Reyes‐Soffer, Carlos Rondon-Clavo, Henry N. Ginsberg · 2011 · Expert Opinion on Pharmacotherapy
51. Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients
    Nanette Kass Wenger, Sandra J. Lewis · 2010 · Current Gerontology and Geriatrics Research
52. Evidence for statin therapy in polycystic ovary syndrome
    Thozhukat Sathyapalan, Stephen Lawrence Atkin · 2010 · Therapeutic Advances in Endocrinology and Metabolism
53. Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function
    PRAKASH C. DEEDWANIA · 2014 · Postgraduate Medicine
54. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective
    Richard M. Cubbon, Matthew Kahn, Mark T. Kearney · 2007 · International Journal of Clinical Practice
55. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study
    Petra M. Gorter, Frank L.J. Visseren, Ale Algra, Yolanda van der Graaf, on behalf of the SMART Study Group · 2007 · Diabetic Medicine
56. Triglycerides: How Much Credit Do They Deserve?
    Payal Kohli, Christopher Paul Cannon · 2012 · Medical Clinics of North America
57. Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials
    Sandra J. Hamilton, Gerald Francis Watts · 2013 · The Review of Diabetic Studies
58. Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience
    Daisuke Koya, Vito M. Campese · 2013 · Journal of Atherosclerosis and Thrombosis
59. Improved Outcome after Primary Vitrectomy in Diabetic Patients Treated with Statins
    Raimo Tuuminen, Sari Sahanne, Jari K. Haukka, Sirpa Loukovaara · 2015 · European Journal of Ophthalmology
60. Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus
    Liu, Zhi, Xu, Yueqiao, Hao, Hengjian, Yin, Chunlin, Xu, Ji, Li, Jing, Wang, Yanling, Xu, Dong · 2016 · International Journal of Cardiology
61. Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East
    Khalid Al‐Rasadi · 2011 · The Open Cardiovascular Medicine Journal
62. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER
    B.W. Karlson, Philip J. Barter, M K Palmer, Pia Lundman, Stephen James Nicholls · 2012 · Nutrition Metabolism and Cardiovascular Diseases
63. Trends in the use of lipid‐lowering drugs by outpatients with diabetes in Taiwan, 1997–2003
    Chi‐Wen Chiang, Hui‐Fen Chiu, Chi‐Yu Chen, Hsin‐Lung Wu, Chun‐Yuh Yang · 2007 · Pharmacoepidemiology and Drug Safety
64. Pharmacological interventions for heart failure in people with chronic kidney disease
    Pietro Ravani, Robert Ross Quinn, Giovanni FM Strippoli · 2016 · Cochrane Database of Systematic Reviews
65. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007–2016
    Hamid Malekzadeh, Mojtaba Lotfaliany, Afshin Ostovar, Farzad Hadaegh, Fereidoun Azizi, Moein Yoosefi, Farshad Farzadfar, Davood Khalili · 2020 · Scientific Reports
66. Statins: Cholesterol guidelines and Indian perspective
    AnilS Menon, Narendra Kotwal, Yashpal Singh, R. Girish · 2015 · Indian Journal of Endocrinology and Metabolism
67. Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines
    R. E. Anderson, Kerstin Brismar, Torbjörn Ivert · 2007 · Diabetes and Vascular Disease Research
68. Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels?
    Devindra Sehra, Sudhish Sehra, Shiv Tej Sehra · 2017 · Expert Opinion on Drug Safety
69. Cardiovascular outcomes trials with statins in diabetes
    Fariha Naeem, Gerard A. McKay, Miles Fisher · 2018 · British Journal of Diabetes
70. Cardiovascular Prevention in Patients with Diabetes and Prediabetes
    Matteo Anselmino, H. Gohlke, Linda Mellbin, Lars Rydén · 2008 · Herz
71. ¿Es posible alcanzar en la práctica clínica los objetivos de control metabólico establecidos para pacientes con diabetes mellitus tipo 1
    Glòria Baena, Florentino Carral, M. Roca, Manuel Cayon, Jose Ortego-Rojo, Luis Escobar, Isabel Torres, Inmaculada Gavilán, Inmaculada Doménech, A. Moral Garcia et al. · 2008 · Endocrinología y Nutrición
72. Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don’t know
    Juliana C.N. Chan, Siew Pheng Chan, Chaicharn Deerochanawong, Ruby T. Go, Kok‐Onn Lee, Ronald C.W., Changyu Pan, Wayne Huey‐Herng Sheu, Philip J. Barter · 2011 · Diabetes Research and Clinical Practice
73. Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman
    Ibrahim S Al-Zakwani, Kadhim Sulaiman, Khalid Al‐Rasadi, Dimitri P. Mikhailidis · 2011 · Current Medical Research and Opinion
74. Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of these guidelines as an educational tool for neurologists. Endorsed by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Preventive Cardiovascular Nurses Association
    James Frederick Meschia, Cheryl Bushnell, Bernadette M Boden-Albala, Lynne T. Braun, Dawn M. Bravata, Seemant Chaturvedi, Mark A. Creager, Robert H. Eckel, Myriam Fornage, Larry B. Goldstein et al. · 2014
75. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines
    Jennifer G. Robinson, Kausik Kumar Ray · 2016 · Arteriosclerosis Thrombosis and Vascular Biology
76. Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study
    Hiroshi Itoh, Issei Komuro, Masahiro Takeuchi, Takashi Akasaka, Hiroyuki Daida, Yoshiki Egashira, Hideo Fujita, Jitsuo Higaki, Ken‐ichi Hirata, Shun Ishibashi et al. · 2018 · Diabetes Obesity and Metabolism
77. Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania
    Aneth Telesphore Bideberi, Reuben Mutagaywa · 2022 · Diabetes Metabolic Syndrome and Obesity
78. Dyslipidemia
    G.B. John Mancini, Robert Alexander Hegele, Lawrence A. Leiter · 2013 · Canadian Journal of Diabetes
79. Lipid‐Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High‐Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy
    H Vaverková, Michel Farnier, Maurizio Rocco Averna, Luc H. Missault, Margus Viigimaa, Qian Dong, Arvind Kumar Shah, Amy O. Johnson‐Levonas, Philippe Brudi · 2010 · Cardiovascular Therapeutics
80. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry
    Anselm Kai Gitt, Claus Juenger, Christina Jannowitz, Barbara Karmann, Juergen Senges, Kurt P Bestehorn · 2009 · European Journal of Cardiovascular Prevention & Rehabilitation
81. Effects of alternative dietary lipid sources on growth performance, health status and fillet fatty acid composition of hybrid sturgeon ( Acipenser baeri Brandt ♀ × Acipenser schrenckii Brandt ♂)
    Huanhuan Yu, Wei Xing, Tieliang Li, Guanling Xu, Zhihong Ma, Na Jiang, Lin Luo · 2020 · Aquaculture Nutrition
82. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers
    Christina L. Aquilante, Michael F. Wempe, Maha S. Sidhom, Lisa A. Kosmiski, Julie A. Predhomme · 2013 · European Journal of Clinical Pharmacology
83. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non‐Familial Hypercholesterolemia
    Jennifer G. Robinson · 2016 · Progress in Cardiovascular Diseases
84. Temporal Trends of High‐Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention
    Aref A. Bin Abdulhak, Mary Vaughan‐Sarrazin, Peter J. Kaboli, Phillip A. Horwitz, Hilary J. Mosher, Garðar Sigurðsson, Nicholas E. Walker, Robert B. Wallace, Jennifer G. Robinson · 2018 · Journal of the American Heart Association
85. Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset
    Maximilian Gabler, Nils Picker, Silke Geier, Ludwin Ley, Jens Aberle, Michael Lehrke, Stéphan Martin, Matthias Riedl, Thomas Wilke · 2021 · Diabetes Therapy
86. Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study
    Tsuyoshi Nozue, Shingo Yamamoto, Shinichi Tohyama, Kazuki Fukui, Shigeo Umezawa, Yuko Onishi, Tomoyuki Kunishima, Akira Sato, Toshihiro Nozato, Shogo Miyake et al. · 2014 · Cardiovascular Diabetology
87. Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
    Antonio Hernández‐Mijares, Juan Francisco Ascaso, Mariano Blasco, Ángel Brea, Ángel Díaz Rodríguez, Teresa Mantilla, Juan Pedro‐Botet, Xavier Pintó, Jesús Millán · 2018 · Clínica e Investigación en Arteriosclerosis
88. Combination drug–diet therapies for dyslipidemia
    Todd Christopher Rideout, Scott Harding, Christopher P. F. Marinangeli, Peter J.H. Jones · 2010 · Translational research
89. Treat to Goal: Impact of Clinical Pharmacist Referral Service Primarily in Diabetes Management
    Thomas M. Henry, Steven A. Smith, Michael D. Hicho · 2013 · Hospital Pharmacy
90. Long-term all-cause and cardiovascular mortality following incident myocardial infarction in men and women with and without diabetes: Temporal trends from 1998 to 2009
    Lee J. Nedkoff, Matthew William Knuiman, Joseph Hung, Tom G. Briffa · 2016 · European Journal of Preventive Cardiology
91. Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention
    Juan Wang, Dan Chen, Dabing Li, Xin Yu, Guo-Bing Shi · 2016 · Medicine
92. Dietary fat composition and cardiac events in patients with type 2 diabetes
    Ana Luiza Teixeira dos Santos, Tanara Weiss, Camila Kümmel Duarte, Jorge Luiz Gross, Mirela Jobim de Azevedo, Themis Zelmanovitz · 2014 · Atherosclerosis
93. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes
    John R. Guyton, Ronald B Goldberg, Theodore Mazzone, Ruth S. Weinstock, Adam B. Polis, Elizabeth Rosenberg, Andrew M. Tershakovec · 2008 · Journal of clinical lipidology
94. Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes
    Vibe Skov, Claudia Cangemi, Jeppe Gram, Mette Marie Hougaard Christensen, Ellen Grodum, Ditte Sørensen, William Scott Argraves, Jan Erik Henriksen, Lars Melholt Rasmussen · 2013 · Diabetes Care
95. Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients
    DAVID H. FITCHETT, Lawrence A. Leiter, Shaun G. Goodman, Anatoly Langer · 2006 · Canadian Journal of Cardiology
96. Life's Essential 8 and risks of cardiovascular morbidity and mortality among individuals with type 2 diabetes: A cohort study
    Hanzhang Wu, Jiahe Wei, Shuai Wang, Wenjuan Chen, Liangkai Chen, Jihui Zhang, Ningjian Wang, Xiao Yan Tan · 2024 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
97. High Risk of Lipoprotein Dysfunction in Type 2 Diabetes Mellitus
    Rafael Carmena · 2008 · Revista Española de Cardiología
98. Removal from the plasma of the free and esterified forms of cholesterol and transfer of lipids to HDL in type 2 diabetes mellitus patients
    Carolina Piras de Oliveira, Raul Cavalcante Maranhão, Marina P Bertato, BERNARDO LEO WAJCHENBERG, Antônio Carlos Lerário · 2012 · Lipids in Health and Disease
99. Management of Lipids in Patients with Diabetes
    Ngozi D. Mbue, John E. Mbue, JANE A. ANDERSON · 2017 · Nursing Clinics of North America
100. Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE
     Jennifer G. Robinson · 2007 · Current Atherosclerosis Reports